MiRxes, PT Elion to Develop Cancer Tests for Indonesian Population
As part of the arrangement, PT Elion will validate MiRxes' microRNA-based tests for stomach and lung cancer in an Indonesian cohort.
MiRxes Launches Study for Pulmonary Hypertension Biomarkers in Asian Populations
The Singapore-based biotech company will evaluate its miRNA biomarker assay for early detection of pulmonary hypertension as part of the SPHERE study.
MiRxes, Singapore Healthcare Organizations Partner to Develop Multi-Cancer Early Detection Test
Under a memorandum of understanding, the partners will share IP rights and any resulting testing kits will be developed, manufactured, and commercialized by MiRxes.
The firm said it has long-term plans to launch multiple miRNA screening tests for cancers that would run in labs or at the point of care using one blood sample.
MiRxes Raises $77M in Series C Round to Speed Progress of Early Cancer Detection Tests
The Singapore-based company's tests look for blood-borne microRNA and other molecular signatures released by cancer and immune cells.